Timber Pharmaceuticals, Inc. (TMBR) Bundle
A Brief History of Timber Pharmaceuticals, Inc. (TMBR)
Foundation and Early Years
Foundation and Early Years
Timber Pharmaceuticals, Inc. was founded in 2018. The company specializes in the development of innovative therapies for dermatological conditions, with a particular focus on orphan diseases such as the rare genetic skin disorder, ichthyosis.
Initial Public Offering
In May 2020, Timber Pharmaceuticals went public on the NYSE American under the ticker symbol TMBR. The IPO raised approximately $7.7 million, an essential milestone for the company, allowing it to fund its clinical trials and further development of its product pipeline.
Product Pipeline Development
Timber's lead product candidate is TMB-001, a formulation of the drug Isotretinoin, targeted for the treatment of congenital ichthyosis. In 2021, the company reported successful Phase 2 clinical trial results, demonstrating a 40% improvement in skin condition over a 12-week period in participants.
Regulatory Milestones
Timber Pharmaceuticals submitted a New Drug Application (NDA) for TMB-001 to the FDA in January 2022. The FDA granted Fast Track designation for TMB-001 in March 2022, which allows for expedited review and development.
Financial Performance
| Year | Revenue (in millions) | Net Income (in millions) | Total Assets (in millions) | Total Liabilities (in millions) |
|---|---|---|---|---|
| 2020 | $0.25 | ($3.21) | $5.8 | $4.2 |
| 2021 | $0.5 | ($5.3) | $10.5 | $7.0 |
| 2022 | $0.75 | ($6.0) | $15.0 | $8.3 |
Recent Developments
As of late 2023, Timber Pharmaceuticals has been preparing for a potential launch of TMB-001, contingent upon FDA approval. The company has also been actively seeking partnerships to enhance its research capabilities and market reach.
Market Position and Challenges
Timber operates within the niche market of dermatological treatments for rare conditions, competing with both established pharmaceuticals and emerging biotech firms. The company faces challenges due to its dependency on a limited product pipeline and the complexities of regulatory approval processes.
A Who Owns Timber Pharmaceuticals, Inc. (TMBR)
Ownership Structure
Ownership Structure
The ownership of Timber Pharmaceuticals, Inc. is comprised of institutional investors, retail investors, and company executives. As of the latest data available, the following table summarizes the ownership distribution:
| Owner Type | Percentage Ownership | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 35.2% | 2,300,000 |
| Retail Investors | 45.5% | 3,000,000 |
| Insider Ownership | 19.3% | 1,200,000 |
Major Shareholders
The following table lists the major shareholders of Timber Pharmaceuticals, indicating the number of shares they own and their corresponding ownership percentages:
| Shareholder Name | Shares Owned | Percentage Ownership |
|---|---|---|
| Vanguard Group | 1,000,000 | 15.0% |
| BlackRock, Inc. | 750,000 | 11.2% |
| Timber Pharmaceuticals Executives | 1,200,000 | 19.3% |
| Other Institutions | 1,050,000 | 15.4% |
Recent Stock Performance
As of the latest trading session, the stock price of Timber Pharmaceuticals (TMBR) was recorded at $2.50 per share, with a market capitalization of approximately $40 million. The stock has shown a fluctuation in the range of $2.00 to $3.00 over the past year.
Financial Overview
For the fiscal year ending December 31, 2022, the financial data is as follows:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $5 million |
| Net Loss | $10 million |
| Total Assets | $15 million |
| Total Liabilities | $8 million |
Recent Developments
In the past year, Timber Pharmaceuticals has raised $15 million in a series A funding round, aimed at advancing its lead product candidate.
Timber Pharmaceuticals, Inc. (TMBR) Mission Statement
Overview of Timber Pharmaceuticals
Timber Pharmaceuticals, Inc. (NASDAQ: TMBR) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare dermatologic diseases.
Core Mission Statement
The mission of Timber Pharmaceuticals is to transform the lives of patients with rare dermatologic conditions by developing effective and safe therapies. The company aims to be a leader in the field of dermatology through the advancement of specialized treatment options that address unmet medical needs.
Key Objectives
- To advance clinical development programs for therapeutics targeting rare skin diseases.
- To collaborate with healthcare professionals and patient advocacy groups to understand patient needs.
- To ensure a sustainable business model that provides value to stakeholders.
Financial Overview
As of Q3 2023, Timber Pharmaceuticals reported total revenues of approximately $3.4 million. The company had cash and cash equivalents of $18.5 million, providing a runway through 2024.
Research and Development Investments
In 2022, Timber Pharmaceuticals allocated $10 million towards research and development, focusing on its two lead product candidates, TMB-001 and TMB-002, for the treatment of rare skin conditions.
Market Position and Strategy
Timber Pharmaceuticals aims to carve a niche in the dermatology market, projected to reach $20 billion by 2025. The company is focused on developing products for conditions such as acne, psoriasis, and other rare dermatologic diseases.
Recent Achievements
- Successful completion of Phase 2 clinical trial for TMB-001 in Q2 2023.
- Partnership established with leading dermatology clinics to enhance clinical research efforts.
Employee and Community Engagement
Timber Pharmaceuticals employs approximately 50 individuals, with a strong emphasis on fostering an inclusive culture. The company actively participates in community outreach and education efforts related to rare skin diseases.
Financial Data Summary
| Financial Metric | Value (Q3 2023) |
|---|---|
| Total Revenues | $3.4 million |
| Cash and Cash Equivalents | $18.5 million |
| R&D Spend (2022) | $10 million |
| Employee Count | 50 |
| Projected Dermatology Market (2025) | $20 billion |
Future Directions
Timber Pharmaceuticals plans to expand its product pipeline by exploring additional indications for its existing therapies and potential new drug candidates, reinforcing its commitment to innovative solutions for dermatological patients.
How Timber Pharmaceuticals, Inc. (TMBR) Works
Company Overview
Timber Pharmaceuticals, Inc. (TMBR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological diseases. As of October 2023, TMBR primarily targets conditions such as acne and other skin disorders, leveraging its proprietary drug delivery technologies.
Business Model
TMBR operates on a model that encompasses the following key components:
- Research and development of novel therapeutics
- Clinical trials to validate efficacy and safety
- Regulatory submission and approval processes
- Partnerships and collaborations for commercialization
Financial Performance
As reported in their latest financial summary, Timber Pharmaceuticals had the following key figures:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue (2022) | $0 |
| Net Loss (Q2 2023) | $(4.1) million |
| Cash Position (as of August 2023) | $10.2 million |
| R&D Expenses (2022) | $(3.5) million |
| General & Administrative Expenses (2022) | $(2.0) million |
Clinical Trials
Timber Pharmaceuticals is engaged in multiple clinical trials for its lead product candidates. The details of these trials are as follows:
| Product Candidate | Phase | Indication | Expected Completion |
|---|---|---|---|
| TMB-001 | Phase 2b | Nodular Basal Cell Carcinoma | Q4 2023 |
| TMB-002 | Phase 2 | Psoriasis | Q1 2024 |
Market Position and Competition
Timber Pharmaceuticals operates in a competitive landscape with key competitors. Below are some of the primary competitors and their market details:
| Company | Market Cap (USD) | Key Products |
|---|---|---|
| Amgen Inc. | $135 billion | Enbrel, Humira |
| AbbVie Inc. | $157 billion | Skyrizi, Rinvoq |
| Dermira, Inc. | $1.1 billion | Leviac, Qbrexza |
Strategic Partnerships
TMBR has formed several strategic alliances to enhance its development pipeline and market reach. The company is in partnership with:
- Dermatology-focused pharmaceutical companies
- Academic institutions for research collaboration
- Contract research organizations (CROs) for clinical trial management
Future Outlook
With upcoming trials and a robust pipeline, Timber Pharmaceuticals aims to advance its therapeutic offerings and expand its market presence. The following projections indicate the company’s anticipated growth:
- Projected FDA approvals in 2024
- Focus on expanding skin disease portfolio
- Anticipated partnerships for commercialization by 2025
How Timber Pharmaceuticals, Inc. (TMBR) Makes Money
Revenue Streams
Timber Pharmaceuticals, Inc. primarily generates revenue through:
- Product Sales: Revenue from pharmaceutical products.
- Partnerships and Collaborations: Income from strategic alliances and licensing agreements.
- Research Grants: Funding received for clinical trials and research activities.
Product Portfolio
The company focuses on developing treatments for dermatological diseases. Key products include:
- TMB-001: A topical formulation for the treatment of epidermolysis bullosa.
- TMB-002: A drug candidate targeting other skin conditions.
Recent Financial Performance
As of Q2 2023, Timber Pharmaceuticals reported the following financial metrics:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $1.5 million |
| Gross Profit | $1.2 million |
| Net Loss | ($4.3 million) |
| Cash and Cash Equivalents | $18 million |
| Research and Development Expenses | $3 million |
| General and Administrative Expenses | $2.5 million |
Market Strategy
Timber Pharmaceuticals employs various strategies to maximize revenue potential:
- Clinical Trials: Conducting advanced clinical trials to ensure product efficacy and safety.
- Regulatory Approvals: Seeking rapid approvals from agencies like the FDA to enhance market readiness.
- Targeted Marketing: Focusing on niche markets for specific dermatological conditions.
Partnerships and Collaborations
The company has established various collaborations to bolster its financial position:
- Partnership with a major pharmaceutical company: For co-development and commercialization of TMB-001.
- Licensing agreements: Generating upfront fees and royalties on product sales.
Investment and Funding
Timber Pharmaceuticals has sought funding through different avenues:
- Public Offerings: Raised $20 million in the IPO conducted in 2022.
- Equity Financing: Secured an additional $12 million in funding from private investors in 2023.
Future Projections
Analyst projections for Timber Pharmaceuticals indicate potential growth in revenue driven by:
- Market Expansion: Targeting new geographical markets for existing products.
- New Product Launches: Anticipated launch of TMB-002 in 2024 expected to increase revenue.
- Increased Demand: Rising prevalence of skin disorders driving market demand.
Timber Pharmaceuticals, Inc. (TMBR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support